Although Fas-mediated cell death may play a role in atherogenesis, causal data in support of this hypothesis are lacking. The present study investigated the possibility that endothelial cells are involved in vascular smooth muscle cell (VSMC) apoptosis via the Fas -FasL pathway, and hence in atherogenesis. FACS analysis detected FasL on the surface of human umbilical vein endothelial cells (HUVECs) and immunofluorescence staining of the HUVECs demonstrated high levels of FasL in the intracellular compartment. FasL was down-regulated 4 h after tumor necrosis factor (TNF ) treatment, coinciding with maximal surface expression of the adhesion molecules vascular cell adhesion molecule-1 and E-selectin. However, the down-regulation of FasL expression was transient, as surface expression returned within 24 h of TNF treatment. When cocultured with VSMCs, the FasL-expressing EC could kill the VSMCs in a manner that could be blocked by recombinant Fas-Fc, deployed as a soluble receptor for Fas. Moreover, when human coronary arteries were studied with immunohistochemistry using G247-4 monoclonal antibody for the detection of FasL, few FasL positive EC were observed in diffuse intimal thickening. In contrast, endothelium overlying the plaque showed prominent and uniform expression of FasL. These findings suggest that the Fas/FasL pathway can be used by EC to induce VSMC apoptosis in the atherosclerotic lesion. (Jpn Circ J 2001; 65: 556 -560) 
he characteristic atherosclerotic lesion consists of a necrotic core contained within a fibrous capsule comprised of vascular smooth muscle cells (VSMCs). 1 Ultimate failure of this capsule, the 'fibrous cap', is fundamental to the pathogenesis of plaque rupture and acute coronary artery occlusion. Although several cytokines might contribute to cell death in the plaque, the best-defined death pathway is that initiated by the ligands for the death receptors, Fas and tumor necrosis factor (TNF )R1. 2, 3 Fas expression has been detected in both normal and diseased vessel walls, and it has been proposed that Fas-mediated apoptosis is a feature of atherogenesis, [4] [5] [6] atherosclerotic plaque instability, 7 and allograft arteriopathy. 8 Considerable attention has been directed to expression of the Fas ligand (FasL) in activated lymphocytes, especially in lymph nodes, where FasL prevents the expansion of irrelevant lymphocyte clones. Although Fas-mediated cell death may play a role in atherogenesis, causal data in support of this hypothesis are lacking, so the present study investigated the possibility that endothelial cells (EC) are involved in the VSMC apoptosis via the Fas-FasL pathway, and hence in atherogenesis.
The present study demonstrates that as previously reported, cultured endothelial cells (ECs) express FasL. When cocultured with VSMCs, EC-derived FasL kills VSMCs in a manner that can be blocked by Fas-Fc fusion protein, deployed as a soluble receptor for Fas. Specificity of this effect for plaque endothelium, contrary to a published report, 9 is supported by our evidence that FasL is expressed by ECs within human coronary atherosclerotic plaque but not by endothelium overlying non-atherosclerotic intima. These data suggest that the Fas/FasL system may play an important role in the progression of atherosclerotic lesions.
Methods

Cell Culture
Human VSMCs were isolated from the media of the aorta of a 55-year-old organ donor, without evidence of atherosclerosis. The cells were grown in Dulbecco's modified Eagle's medium-high glucose (DMEM) (Life Technology, Grand Island, NY, USA) supplemented with 15% fetal bovine serum (FBS), 5 mmol/L L-glutamine, plus 50 units/ml penicillin and 50 g/ml streptomycin in a humidified atmosphere of 5% CO2. Cells were used through passage 10 in this study. Human umbilical vein endothelial cells (HUVECs; Clontetics) (San Diego, CA, USA) were cultured in endothelial growth medium (EGM; Clonetics) and used passage 3 in this study. HUVECs were treated with TNF (100 ng/ml) in DMEM with 1% FBS. The plates were incubated at 37°C with 5% CO2 for 24 h. Subsequently, the expressions of FasL (Fas -Fc fusion protein; Immunex, Seattle, WA, USA), E-selectin (P6E2; Cytel, La Jolla, CA, USA), and vascular cell adhesion molecule (VCAM)-1 (gift of Dr Tim Carlos, University of Pennsylvania) were examined by flow cytometric analysis (FACS).
Induction of VSMCs Apoptosis by Cocultured Endothelial Cells
To estimate cell death in cell-to-cell contact experiments, a chromium release assay was used 10 in which the amount of 51 Cr released into culture supernatant by VSMCs exposed to ECs reflects the magnitude of cell death. To calibrate the assay, 51 Cr release was determined from normal VSMCs in 15% FBS as well as 51 Cr release in staurosporine-(Sigma, St Louis, MO, USA) treated VSMCs, which induces 100% cell death within 24 h. The data are presented relative to the calibrated values. VSMCs were plated into 24-well plates at 40-50% confluence and preincubated with 51 Cr for 4 h. After 2 washes with phosphate buffered saline (PBS), ECs were added to the wells and chromium release was measured after incubation for 24 h. VSMCs were also preincubated with soluble Fas -Fc fusion protein (50 mg/ml) to investigate the involvement of the Fas -FasL pathway. An effector to target ratio of 20:1 was used in these experiments.
Flow Cytometric Analyses
HUVECs were incubated with the indicated concentrations of primary antibody [P6E2 (10 mg/ml) for the detection of E-selectin (Cytel), anti-VCAM-1 (gift of Dr Tim Carlos, University of Pennsylvania) 10 mg/ml or Fas -Fc fusion protein (Immunex, Seattle, USA) 20 mg/ml] for 30 min at 4°C and then labeled with secondary anti-mouse IgG conjugated with fluorescein isothiocyanate (FITC) (Jackson Laboratories, Bar Harbor, ME, USA). For FasL detection, biotinylated mouse anti-human IgG1 (Fcspecific, Jackson Laboratories) was used. HUVECs were fixed with 1% formaldehyde in PBS (137 mmol/L NaCl, 8.10 mmol/L Na2HPO4 · 12H2O, 8.10 mmol/L Na2HPO4 · 7H2O, 8.10 mmol/L Na2HPO4 anhydrous, 2.68 mmol/L KCl, 1.47 mmol/L KH2PO4; pH 7.4) and 10 4 cells were counted for each experiment.
Tissue Collection and Preparation
Human cardiac tissues were obtained from hearts removed from patients with end-stage ischemic cardiomyopathy (n=13) or idiopathic dilated cardiomyopathy (n=7) (14 males, 6 females, all 26-72 years of age). Thirty-one coronary artery segments were dissected from the hearts and placed in 10% neutral buffered formalin within 2 h. After overnight fixation, the tissue samples were routinely processed and embedded in paraffin. These segments were classified into 2 groups by classic histological criteria: (1) non-atherosclerotic diffuse intimal thickening (DIT; n=11), 
Immunocytochemistry
Either the indirect avidin-biotin-horseradish-peroxidase or alkaline phosphatase visualization method was used as described previously (ABC standard and Elite, Vector Red, Vector Laboratories, Burlingame, CA, USA). 11 Primary antibodies included G247-4 monoclonal antibody (dilution 1:100) for the detection of FasL (PharMingen, San Diego, CA, USA), and CD31 monoclonal antibody (dilution 1:100) for the detection of EC (DAKO)
Statistical Analysis
The cell death assays were performed using 1-3 wells per condition and repeated 3-6 times in separate experiments. Because data distribution was not normal, non-parametric statistical analysis was performed (Kruskal -Wallis or Mann -Whitney rank sum test), using SPSS software (Chicago, IL, USA). A p-value less than 0.05 was considered statistically significant.
Results
FasL is Present on the Cell Surface of Endothelial Cells
We confirmed the expression of cell surface FasL in HUVECs by FACS using Fas -Fc fusion protein (Fig 1) . This detection was specific for FasL as demonstrated by the minimal staining observed with secondary anti-human IgG alone (Fig 1, control samples) . Furthermore, this staining could be completely abolished by the addition of recombinant human FasL (results not shown). Immunofluorescence staining of HUVECs with monoclonal anti-FasL antibody (#33) demonstrated high levels of FasL in the intracellular compartment, with a morphologic appearance suggestive of cytoplasmic vesicles (Fig 2A,B) .
TNF Transiently Down-Regulates FasL Expression on the Surface of Endothelial Cells
As previously reported, 9 FasL was down-regulated 4 h after TNF treatment, coinciding with maximal surface expression of the adhesion molecules VCAM-1 and Eselectin (Fig 1) . However, in contrast to the published report, we extended our observations to 24 h post-TNF treatment and found that the down-regulation of FasL expression was transient, as surface expression returned within 24 h of TNF treatment. To confirm these results, we performed immunofluorescence experiments in HUVECs. As shown in Fig 2C, the vesicular pattern of FasL disappeared in HUVECs treated with TNF for 4 h, indicating that FasL is either degraded or released by the treatment (Fig 2B,C) . However, we did not detect soluble FasL in the culture medium supernatant (data not shown).
Fas-Fc Fusion Protein Inhibits VSMC Apoptosis Induced by Endothelial Cells in Coculture
We next tested whether EC FasL is functionally relevant by examining VSMC apoptosis in a defined coculture system. Because FasL-induced killing of VSMCs requires the addition of cycloheximide, 12 we seeded ECs into cultured 51 Cr-labeled VSMCs in cycloheximide-containing media. As shown in Fig 3, the VSMCs released significant 51 Cr into the media when cultured in the presence of ECs and this EC-mediated 51 Cr release was specific, as the addition of Fas-Fc fusion protein inhibited it (Fig 3) .
FasL is Present in Human Atherosclerotic Plaque
Because questions have been raised about the sensitivity and specificity of some anti-FasL antibodies, 13, 14 we surveyed several antibodies by immunohistochemistry and Western blotting. A number of 'FasL' antibodies have been shown to recognize multiple proteins by Western blotting, rendering interpretation of previously published reports difficult. 23,24 The G247-4 antibody, in contrast, has been shown to yield FasL-specific signals by Western blot in FasL-transfected cells. 14 Using immunohistochemistry of testes, vessel wall and placentas, we found that all of the antibodies except G247-4 produced either a diffuse stain or were inconsistent. G247-4 was highly reproducible, as reported by others, 14 and all further studies were done using this antibody and sections of placenta as a positive control (data not shown). 15 In DIT, minimal immunoreactive FasL was present in endothelium, media, and intima (Fig 4A-D) . In atheroma, FasL was expressed by EC (Fig 4E-H) . Quantitation of FasL immunoreactive EC in overlying DIT (n=11) and atheroma (n=20) was found to be 14±3% and 73±6%, respectively.
Discussion
The data in this study show that in vivo ECs express FasL in the atherosclerotic plaque and in vitro these same cells are also able to induce VSMC apoptosis by a Fas/FasLdependent mechanism. This suggests that the Fas/FasL system is used by EC to induce VSMC apoptosis in the atherosclerotic lesion.
In contrast to our observations of FasL in endothelium, a previous report claimed that FasL is universally present in normal endothelium but lost from ECs at sites of inflammation. 9 If these observations were true, given the immunoprotective role of FasL in the cornea and testis, 16, 17 such wide expression of FasL would imply a hitherto unsuspected systemic role for the endothelium as an immunologic barrier able to kill activated T-cells. However, the antibodies used in that previous study have been shown by others to be ambiguous. 13, 14 In our studies, we used an antibody (G247-4) with better-defined specificity, 14 and confirmed that specificity with isotype matched non-specific mouse IgG1 as a negative control and by specificity of the staining pattern in placenta (data not shown). 15 We observed few FasL positive EC in DIT, whereas the endothelium overlying the plaque showed prominent and uniform expression of FasL. Therefore, we conclude that FasL is upregulated in plaque endothelium.
Functionality of endothelial FasL is suggested by our studies in cell culture in which we found that EC cocultured with SMC labeled with 51 Cr induced the release of 51 Cr into the media, a finding that is particularly relevant to vascular remodeling, because endothelial denudation in the arterial wall results in intimal hyperplasia. 18 Moreover, during endothelial recovery after denudation, areas that are covered by EC show less intimal hyperplasia compared with the uncovered areas. 18 Spontaneous death of SMC in close proximity to EC was reported more than 20 years ago, 19 so all the research to date indicates that the endotheliumsmooth muscle interaction induces SMC death. However, it is also known that endothelial cell -smooth muscle cell interactions are frequent, and that this process activates latent tissue growth factor , a potent modulator of both SMC and EC. 20 Why it is that EC -SMC interactions in such situations occur without inducing observable cell death is unclear.
The central features of atherosclerotic lesion progression are narrowing of a vessel and break-down of the fibrous cap that encapsulates the accumulation of lipid that comprises the fatty core of the plaque. Although the present study focused on cell death in VSMCs, these features may depend on the relationship between cell proliferation and death. Quantitative evidence on rates of cell death in plaque is available from Thomas' elegant application of cell kinetics in pig vessels responding to hypercholesterolemia. 21 The finding was that smooth muscle replication was far in excess of rates of change in cell number and that the death was perimitotic. Consistent with Thomas' data, Bennett et al found that death of plaque SMC is enhanced when cells are forced to replicate in the presence of excess p53, 22 which suggests that plaque SMC death may be dependent on a death pathway associated with replication that can be at least regulated by p53.
In conclusion, this paper describes the induction of VSMC apoptosis by ECs, an effect that may partially influence vessel remodeling and the response to injury.
